Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series

Abdul Wali Khan , Simran Chandra , Himil Mahadevia , Janakiraman Subramanian , Ben Ponvilawan , Dhruv Bansal

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002347

PDF (711KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002347 DOI: 10.37349/etat.2025.1002347
Case Report
research-article
Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series
Author information +
History +
PDF (711KB)

Abstract

Immune checkpoint inhibitors (ICIs) are established treatments for various malignancies, including lung, kidney, and colorectal cancers. However, their broad use has led to an increase in immune-related adverse events (irAEs), with thyroiditis, colitis, and pneumonitis being the most common. Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe irAE characterized by excessive immune activation, leading to systemic inflammation and multi-organ dysfunction. We present three cases of ICI-induced HLH in patients with lung cancer who were treated with ICIs. All patients showed elevated inflammatory markers and responded to high-dose corticosteroids without the addition of etoposide. These cases underscore the importance of early recognition and treatment of HLH in patients receiving ICIs to mitigate morbidity and mortality. Large-scale studies are needed to establish standardized guidelines for diagnosing and managing ICI-induced HLH.

Keywords

immune checkpoint inhibitors / HLH / lung cancer

Cite this article

Download citation ▾
Abdul Wali Khan, Simran Chandra, Himil Mahadevia, Janakiraman Subramanian, Ben Ponvilawan, Dhruv Bansal. Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in lung cancer: a case series. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002347 DOI:10.37349/etat.2025.1002347

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Small Cell Lung Cancer [Internet]. National Comprehensive Cancer Network; c2025 [cited 2025 Sep 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

[2]

Colon Cancer [Internet]. National Comprehensive Cancer Network; c2025 [cited 2025 Sep 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

[3]

Kidney Cancer [Internet]. National Comprehensive Cancer Network; c2025 [cited 2025 Sep 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

[4]

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017; 28: 2377-85.

[5]

Henter JI. Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2025; 392: 584-98.

[6]

Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997; 28: 342-7.

[7]

Takahashi H, Koiwa T, Fujita A, Suzuki T, Tagashira A, Iwasaki Y. A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy. Respir Med Case Rep. 2020; 30: 101097.

[8]

Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, Yamazaki N. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatol Ther. 202; 33: e13321.

[9]

Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018; 6: 49.

[10]

Dupré A, Michot JM, Schoeffler A, Frumholtz L, Baroudjian B, Delyon J, et al. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. Br J Haematol. 2020; 189: 985-92.

[11]

Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018; 11: 31.

[12]

Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 200; 48: 124-31.

[13]

Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66: 2613-20.

[14]

von Itzstein MS, Khan S, Gerber DE. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. Clin Chem. 2020; 66: 779-93.

[15]

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res. 2018; 6: 1093-9.

PDF (711KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉